NCT05724316

Brief Summary

This study aims to understand how vitamin D (VD) affects human health. Typically, prisoners are low on vitamin D, as it is difficult to receive through diet, and is mostly obtained via exposure to the sun. The investigators predict that VD supplements could help improve overall mental well-being, as well as improve bone health. The investigators aim to recruit two groups of participants from a United Kingdom (UK) Prison, all of whom will participate via an informed consent process. The first group of prisoners will have chosen to take VD supplements, the second group will have chosen not to take VD supplements. At the start of the study, prisoners will have their bone density and blood VD levels tested. The investigators will also ask participants to complete a series of questionnaires to understand the state of mental well-being at the start of the study. Participants will be asked to complete a food diary to track dietary intake over the following week. Additionally, the investigators are interested in identifying what proportion of participants have a specific genetic makeup relating to their ability to metabolise VD, and participants will be asked to provide a saliva sample to test this. Every month following the start of the study, participants will be asked to complete the same questionnaires and food diary again. On the 3rd month, the investigators will again test the participants' bone density and blood levels of VD, to see whether supplementation has improved participant VD status. This study will run for a minimum of 3 months, up to a maximum of 6.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 21, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 13, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

March 18, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2024

Completed
Last Updated

November 2, 2023

Status Verified

November 1, 2023

Enrollment Period

10 months

First QC Date

December 21, 2022

Last Update Submit

November 1, 2023

Conditions

Keywords

AnxietyDepressionBehaviourMental healthMental wellbeingPhysical healthBone healthPrisoners

Outcome Measures

Primary Outcomes (6)

  • Mental wellbeing

    Overall mental well-being as measured by The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). WEMWBS uses a five-point scale, with participants required to answer questions recalling from the previous 2 weeks. The minimum score is 14, the maximum score is 70. A high score indicates lower well-being.

    Baseline

  • Mental wellbeing

    Overall mental well-being as measured by The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). WEMWBS uses a five-point scale, with participants required to answer questions recalling from the previous 2 weeks. The minimum score is 14, the maximum score is 70. A high score indicates lower well-being.

    End of Month 1

  • Mental wellbeing

    Overall mental well-being as measured by The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). WEMWBS uses a five-point scale, with participants required to answer questions recalling from the previous 2 weeks. The minimum score is 14, the maximum score is 70. A high score indicates lower well-being.

    End of Month 2

  • Mental wellbeing

    Overall mental well-being as measured by The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). WEMWBS uses a five-point scale, with participants required to answer questions recalling from the previous 2 weeks. The minimum score is 14, the maximum score is 70. A high score indicates lower well-being.

    End of Month 3

  • Vitamin D serum levels

    Assessing the levels of serum vitamin D amongst participants, using blood serum. 25(OH)D of \< 20 ng/ml is considered vitamin D deficiency, and 25(OH)D of 21-29 ng/ml is considered insufficient.

    Baseline

  • Vitamin D serum levels

    Assessing the levels of serum vitamin D amongst participants, using blood serum. 25(OH)D of \< 20 ng/ml is considered vitamin D deficiency, and 25(OH)D of 21-29 ng/ml is considered insufficient.

    End of month 3

Secondary Outcomes (18)

  • Rule Violations

    Baseline

  • Rule Violations

    End of Month 3

  • Aggression

    Baseline

  • Aggression

    End of Month 1

  • Aggression

    End of Month 2

  • +13 more secondary outcomes

Study Arms (2)

Vitamin D Group

EXPERIMENTAL

All participants in this group will receive cholecalciferol (VD3 25μg) tablets, one to be taken per day.

Dietary Supplement: Vitamin D supplement

Control Group

NO INTERVENTION

Will receive no vitamin D supplements.

Interventions

Vitamin D supplementDIETARY_SUPPLEMENT

N/A (says not to repeat information here)

Also known as: cholecalciferol (VD3 25μg) tablet
Vitamin D Group

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Long-term Residents (with minimum 1 year)
  • Biological Male adults (+18)
  • Have been residents for minimum of 3 months
  • Understanding of the English language

You may not qualify if:

  • Short term Residents (\<1 year), residents at end of their sentence
  • Residents with conditions impacting nutrient absorption i.e. Crohn's disease/celiac disease
  • Residents already taking calcitriol (an active form of VD)
  • Any medical condition that would preclude a participant from taking VD supplements
  • Any medical condition which could interfere with VD metabolism

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HMP Huntercombe

Henley on Thames, RG9 5SB, United Kingdom

RECRUITING

MeSH Terms

Conditions

DepressionAnxiety DisordersBone Diseases, MetabolicVitamin D DeficiencyBehaviorPsychological Well-Being

Interventions

CholecalciferolTablets

Condition Hierarchy (Ancestors)

Behavioral SymptomsMental DisordersBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersPersonal Satisfaction

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipidsDosage FormsPharmaceutical Preparations

Study Officials

  • Jonathan Tammam

    Oxford Brookes University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: One arm will receive vitamin D supplements, the other arm will not receive supplements.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director Centre for Nutrition and Health

Study Record Dates

First Submitted

December 21, 2022

First Posted

February 13, 2023

Study Start

March 18, 2023

Primary Completion

January 1, 2024

Study Completion

March 1, 2024

Last Updated

November 2, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Due to the nature of the participants included, we are undecided on whether raw data will be shared at this time. This will be reviewed later on with the collaborators.

Locations